Page 2,644«..1020..2,6432,6442,6452,646..2,6502,660..»

Symposium attracts top stem cell researchers

Posted: September 20, 2012 at 11:21 am

BRIDGEWATER Scientists from all over the country gathered for the sixth annual New Jersey Stem Cell Research Symposium on Wednesday at the Bridgewater Marriott hotel.

Researchers presented discoveries to an audience of about 250 people, with the University contributing 42 displays on findings in fields ranging from leukemia to addiction.

The symposium was designed to help different personnel in the field meet to boost productivity, said Kathryn Drzewiecki, a University graduate student in biomedical engineering.

Its good to have research and industry together to help each other, said Drzewiecki, who studied devices meant to culture stem cells. We can tell them what they need and they can get those products to be developed.

The Universitys Center for Stem Cell Research co-sponsored the symposium.

Ron Hart, professor of cell biology and neuroscience at the University, said the University is on the forefront of stem cell research and has the largest collection of human blood cells in the world. Half a million samples are stored in the Cell and DNA Repository and are now being used to generate stem cells for research, he said.

We turn them into neurons and begin to study mechanisms of disorders, Hart said. So there are several labs in Rutgers that are dealing with various diseases. Thats what makes our University special in this aspect.

Among the projects featured at the symposium was a new machine introduced by Life Technologies, a global life-sciences company, designed to copy a genome sequence quicker and cheaper than before.

Although the machine, called the Ion Proton Sequencer, costs $200,000, the chip used to take tissue samples has been reduced from its current cost of $500,000 to about $1,000, said Marsha Slater, application specialist for Life Technologies.

Thats going to create a lot of change in how medicine is done, Slater said. Cancer patients will be able to get their tissue samples sequenced, see what mutations are there which will help choose the best chemotherapy for the patient.

Read more here:
Symposium attracts top stem cell researchers

Posted in Stem Cell Research | Comments Off on Symposium attracts top stem cell researchers

Research suggests promise of cell therapy for bowel disease

Posted: September 20, 2012 at 2:18 am

Public release date: 19-Sep-2012 [ | E-mail | Share ]

Contact: Karen Richardson krchrdsn@wakehealth.edu 336-716-4453 Wake Forest Baptist Medical Center

WINSTON-SALEM, N.C. Sept. 19, 2012 New research shows that a special population of stem cells found in cord blood has the innate ability to migrate to the intestine and contribute to the cell population there, suggesting the cells' potential to treat inflammatory bowel disease (IBD).

"These cells are involved in the formation of blood vessels and may prove to be a tool for improving the vessel abnormalities found in IBD," said lead author Graca Almeida-Porada, M.D., Ph.D., a professor at Wake Forest Baptist Medical Center's Institute for Regenerative Medicine. The research is published in the current print issue of the journal Hepatology.

Up to 1 million Americans have IBD, which is characterized by frequent diarrhea and abdominal pain. IBD actually refers to two conditions ulcerative colitis and Crohn's disease in which the intestines become red and swollen and develop ulcers. With IBD, blood vessels in the intestine leak and contribute to inflammation.

While there is currently no cure for IBD, there are drug therapies aimed at reducing inflammation and preventing the immune response. However, these therapies aren't always effective. The long-term aim of the research is to develop an injectable cell therapy to induce tissue recovery.

The work, performed while Almeida-Porada was at the University of Nevada, also involved colleagues from Indiana University School of Medicine. The researchers studied a special population of cells, known as endothelial colony-forming cells, found in cord blood, bone marrow and circulating blood. The finding in 1997 that the cells can contribute to blood vessel formation in adults, not just embryos, initiated the notion of using them for therapy. Studies in humans have validated the ability of these cells to improve reduced blood flow to the limbs and to treat heart diseases.

However, there have been few studies to explore the inherent biologic ability of these cells to home to different organs and contribute to tissue-specific cell populations. Evaluating their potential to migrate to the intestine was an obvious choice, said Almeida-Porada, because dysfunctional blood vessels are a hallmark of IBD. Not only are circulating levels of vessel-forming cells reduced in patients with IBD, but a key factor in IBD progression is the development of abnormal or immature blood vessels, which leads to chronic inflammation.

The cells were injected into fetal sheep at 59 to 65 days gestation. About 11 weeks later, intestinal tissue was analyzed to detect the presence of the human cells. The researchers found that the human cells had migrated to the intestine and contributed significantly to the cell population there.

"This study shows that the cells can migrate to and survive in a healthy intestine and have the potential to support vascular health," said Almeida-Porada. "Our next step will be to determine whether the cells can survive in the 'war' environment of an inflamed intestine."

Go here to see the original:
Research suggests promise of cell therapy for bowel disease

Posted in Stem Cell Videos | Comments Off on Research suggests promise of cell therapy for bowel disease

Promise of cell therapy for bowel disease

Posted: September 20, 2012 at 2:18 am

ScienceDaily (Sep. 19, 2012) New research shows that a special population of stem cells found in cord blood has the innate ability to migrate to the intestine and contribute to the cell population there, suggesting the cells' potential to treat inflammatory bowel disease (IBD).

"These cells are involved in the formation of blood vessels and may prove to be a tool for improving the vessel abnormalities found in IBD," said lead author Graca Almeida-Porada, M.D., Ph.D., a professor at Wake Forest Baptist Medical Center's Institute for Regenerative Medicine. The research is published in the current print issue of the journal Hepatology.

Up to 1 million Americans have IBD, which is characterized by frequent diarrhea and abdominal pain. IBD actually refers to two conditions -- ulcerative colitis and Crohn's disease -- in which the intestines become red and swollen and develop ulcers. With IBD, blood vessels in the intestine leak and contribute to inflammation.

While there is currently no cure for IBD, there are drug therapies aimed at reducing inflammation and preventing the immune response. However, these therapies aren't always effective. The long-term aim of the research is to develop an injectable cell therapy to induce tissue recovery.

The work, performed while Almeida-Porada was at the University of Nevada, also involved colleagues from Indiana University School of Medicine. The researchers studied a special population of cells, known as endothelial colony-forming cells, found in cord blood, bone marrow and circulating blood. The finding in 1997 that the cells can contribute to blood vessel formation in adults, not just embryos, initiated the notion of using them for therapy. Studies in humans have validated the ability of these cells to improve reduced blood flow to the limbs and to treat heart diseases.

However, there have been few studies to explore the inherent biologic ability of these cells to home to different organs and contribute to tissue-specific cell populations. Evaluating their potential to migrate to the intestine was an obvious choice, said Almeida-Porada, because dysfunctional blood vessels are a hallmark of IBD. Not only are circulating levels of vessel-forming cells reduced in patients with IBD, but a key factor in IBD progression is the development of abnormal or immature blood vessels, which leads to chronic inflammation.

The cells were injected into fetal sheep at 59 to 65 days gestation. About 11 weeks later, intestinal tissue was analyzed to detect the presence of the human cells. The researchers found that the human cells had migrated to the intestine and contributed significantly to the cell population there.

"This study shows that the cells can migrate to and survive in a healthy intestine and have the potential to support vascular health," said Almeida-Porada. "Our next step will be to determine whether the cells can survive in the 'war' environment of an inflamed intestine."

The researchers also evaluated the ability of the cells to home to the liver. Smaller numbers of cells reached the liver than the intestine, suggesting that new strategies would be needed to enhance the therapeutic potential for this organ.

The research was supported by the National Heart, Lung, and Blood Institute grants HL097623 and HL073737.

Continue reading here:
Promise of cell therapy for bowel disease

Posted in Stem Cell Videos | Comments Off on Promise of cell therapy for bowel disease

South Korean lawmakers one step from rigorous new system for stem cell Advancement: scientists, physicians and …

Posted: September 20, 2012 at 2:18 am

SEOUL, South Korea, Sept. 19, 2012 /PRNewswire/ -- Seung-Jo Yang, a Parliament member, prepared a bill proposing new law for the management and transplantation of stem cells. On September 17, the National Health and Welfare Committee referred the bill to the Conference for review. The previous 18th National Assembly proposed a similar stem cell bill when much of its term had already passed so it was not fully discussed until the period ended, disappointing many patients with rare diseases. The Bill was referred to the 19th National Assembly, though, which shows the willingness of South Korean leaders to meet the expectations that this new law will be passed coming from the medical community and patient groups throughout South Korea.

Dr. Jeong-Chan Ra, president of RNL BIO's stem cell technology institute said "This effort for new stem cell bill will advance the use and sophistication of autologous adult stem cell technology as a powerful solution for overcoming incurable diseases." Dr. Ra, whose pioneering efforts in Korean stem cell research are known worldwide, is equally known in Korea as an ardent advocate for governmental investment in regenerative medicine. Perhaps no scientist has pushed harder for rigorous standards for stem cell banking, which this proposal may at last bring to fruition.

In South Korea stem cell banks have not been operated under a specific legal structure, so development and progress has been limited. The proposed law suggests that the harvesting and preservation of stem cells must be controlled by national regulation, specifically a management system for stem cell harvesting, storage and implantation. Through this, stem cell experts expect growth in responsible stem cell research and faster, even safer development of therapeutics.

Additionally, the current Korean policy requires stem cell programs - regardless of whether there are available therapies for patients with any particular condition - to complete clinical trial phase III for market approval. Had such rules been in place, for example, for the treatment of H.I.V., tens of thousands of people would have died. Many treatments for those with incurable diseases have been approved without completion of Phase III including stem cell treatments in other nations, even for the treatment of HIV, which stem cells have now cured. The bill under consideration proposes that physicians can use their own stem cells to treat conditions under their discretion if those stem cells are properly expanded, managed, handled and provided to clinicians for them at or above the proposed standards, which is the best news patients with incurable diseases for which no existing cure is available by current medicine have had in a long time.

When the bill is passed, high standards will be established and the better methods will immediately be made obvious to both government and patients. Through this the stem cell community expects a leap in industrial growth, and a leap in the ethical adherence of physicians to do no harm to patients and to provide remedies where possible for the aid of their patients.

The Korean medical community also expects not only to see an influx of domestic patients but also many patients from other nations that lack standards for the growth of patients' own stem cells. South Korea, many economists predict, could become the Mecca for stem cell therapeutics.

Continue reading here:
South Korean lawmakers one step from rigorous new system for stem cell Advancement: scientists, physicians and ...

Posted in Stem Cell Videos | Comments Off on South Korean lawmakers one step from rigorous new system for stem cell Advancement: scientists, physicians and …

Research suggests promise of cell therapy for bowel disease

Posted: September 19, 2012 at 11:13 pm

Public release date: 19-Sep-2012 [ | E-mail | Share ]

Contact: Karen Richardson krchrdsn@wakehealth.edu 336-716-4453 Wake Forest Baptist Medical Center

WINSTON-SALEM, N.C. Sept. 19, 2012 New research shows that a special population of stem cells found in cord blood has the innate ability to migrate to the intestine and contribute to the cell population there, suggesting the cells' potential to treat inflammatory bowel disease (IBD).

"These cells are involved in the formation of blood vessels and may prove to be a tool for improving the vessel abnormalities found in IBD," said lead author Graca Almeida-Porada, M.D., Ph.D., a professor at Wake Forest Baptist Medical Center's Institute for Regenerative Medicine. The research is published in the current print issue of the journal Hepatology.

Up to 1 million Americans have IBD, which is characterized by frequent diarrhea and abdominal pain. IBD actually refers to two conditions ulcerative colitis and Crohn's disease in which the intestines become red and swollen and develop ulcers. With IBD, blood vessels in the intestine leak and contribute to inflammation.

While there is currently no cure for IBD, there are drug therapies aimed at reducing inflammation and preventing the immune response. However, these therapies aren't always effective. The long-term aim of the research is to develop an injectable cell therapy to induce tissue recovery.

The work, performed while Almeida-Porada was at the University of Nevada, also involved colleagues from Indiana University School of Medicine. The researchers studied a special population of cells, known as endothelial colony-forming cells, found in cord blood, bone marrow and circulating blood. The finding in 1997 that the cells can contribute to blood vessel formation in adults, not just embryos, initiated the notion of using them for therapy. Studies in humans have validated the ability of these cells to improve reduced blood flow to the limbs and to treat heart diseases.

However, there have been few studies to explore the inherent biologic ability of these cells to home to different organs and contribute to tissue-specific cell populations. Evaluating their potential to migrate to the intestine was an obvious choice, said Almeida-Porada, because dysfunctional blood vessels are a hallmark of IBD. Not only are circulating levels of vessel-forming cells reduced in patients with IBD, but a key factor in IBD progression is the development of abnormal or immature blood vessels, which leads to chronic inflammation.

The cells were injected into fetal sheep at 59 to 65 days gestation. About 11 weeks later, intestinal tissue was analyzed to detect the presence of the human cells. The researchers found that the human cells had migrated to the intestine and contributed significantly to the cell population there.

"This study shows that the cells can migrate to and survive in a healthy intestine and have the potential to support vascular health," said Almeida-Porada. "Our next step will be to determine whether the cells can survive in the 'war' environment of an inflamed intestine."

The rest is here:
Research suggests promise of cell therapy for bowel disease

Posted in Stem Cells | Comments Off on Research suggests promise of cell therapy for bowel disease

Cytomedix to Present at BIOX; Noble Financial Capital Markets' Life Sciences Exposition

Posted: September 19, 2012 at 7:11 pm

GAITHERSBURG, MD--(Marketwire - Sep 19, 2012) - Cytomedix, Inc. ( OTCQX : CMXI ), a fully integrated regenerative medicine company commercializing and developing innovative platelet and adult stem cell technologies, today announced that Martin P. Rosendale, Chief Executive Officer of Cytomedix, will present a corporate update at BIOX; Noble Financial Capital Markets' Life Sciences Exposition to be held at the University of Connecticut, Stamford Campus on September, 24-25, 2012.Mr. Rosendale's presentation will take place on Monday, September 24th at 8:00 a.m. Eastern time.

In addition to the corporate presentation, Mr. Rosendale will be a participant on the panel presentation titled "Advancements in Cell Therapy & Regenerative Medicine," on September 24th at 11:45 a.m.

Following the event, a high-definition video webcast of the Company's presentation and a copy of the presentation materials will be available on the Company's web site at http://www.cytomedix.com, or through the Noble Financial websites: http://www.noblefcm.com, or http://www.nobleresearch.com/BioExposition.htm. Microsoft SilverLight viewer (a free download from the presentation link) is required to participate. The webcast will be archived on Cytomedix's website for 90 days following the event.

About Noble Financial Noble Financial Capital Markets was established in 1984 and is an equity research driven, full-service, investment banking boutique focused on life sciences, technology and media, emerging growth, companies. The company has offices in New York, Boston, New Jersey, Los Angeles, and Boca Raton, FL. In addition to non-deal road shows and sector-specific conferences throughout the year, Noble Financial hosts its large format annual equity conference in January in South Florida featuring 150 presenting companies from across North America and total attendance of close to 600. For more information: http://www.noblefcm.com.

About Cytomedix, Inc. Cytomedix, Inc. is a fully integrated regenerative medicine company commercializing and developing innovative platelet and adult stem cell separation products that enhance the body's natural healing processes. The Company's advanced autologous technologies offer clinicians a new treatment paradigm for wound and tissue repair. The Company's patient-derived PRP systems are marketed by Cytomedix in the U.S. and distributed internationally.Our commercial products include the AutoloGel System, cleared by the FDA for wound care and the Angel Whole Blood Separation System. The Company is developing novel regenerative therapies using our proprietary ALDH Bright Cell ("ALDHbr") technology to isolate a unique, biologically active population of a patient's own stem cells.A Phase 2 trial evaluating the use of ALDHbr for the treatment of ischemic stroke is underway. For additional information please visit http://www.cytomedix.com.

Safe Harbor Statement Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix' actual results may differ materially due to a number of factors, many of which are beyond Cytomedix' ability to predict or control, including among many others, risks and uncertainties related to the Company's reimbursement related efforts,the Company's ability to capitalize on the benefits of the above-referenced CMS determination, the Company's ability to successfully and favorably conclude the negotiations and related discussions with the above-referenced global pharmaceutical company, the Company's ability to successfully integrate the Aldagen acquisition, to successfully manage contemplated clinical trials, to manage and address the capital needs, human resource, management, compliance and other challenges of a larger, more complex and integrated business enterprise, viability and effectiveness of the Company's sales approach and overall marketing strategies, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGel System as contemplated. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as "believes," "forecasted," "projects," "is expected," "remain confident," "will" and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including our Annual Report on Form 10-K for the year ended December 31, 2011 and other subsequent filings. These filings are available at http://www.sec.gov.

The rest is here:
Cytomedix to Present at BIOX; Noble Financial Capital Markets' Life Sciences Exposition

Posted in Regenerative Medicine | Comments Off on Cytomedix to Present at BIOX; Noble Financial Capital Markets' Life Sciences Exposition

NeoStem to Present at Noble Capital Markets’ Life Sciences Exposition on September 24

Posted: September 19, 2012 at 6:20 pm

NEW YORK, Sept. 19, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a rapidly emerging market leader in the fast growing cell therapy market, today announced that Company management has been invited to participate at BIOX, the Noble Financial Capital Markets' Life Sciences Exposition on Monday, September 24. Company management will make a webcasted company presentation and participate in a cell therapy panel.

Noble Financial Capital Markets Investor Conference - BIOX Life Sciences Exposition

For more information about the conference, please visit http://www.nobleresearch.com/BIOX.htm.

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

For more information on NeoStem, please visit http://www.neostem.com.

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its CDMO business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. Forward looking statements also include statements with respect to satisfying all conditions to closing the disposition of Erye, including receipt of all necessary regulatory approvals in the PRC. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to (i) the Company's ability to manage its business despite operating losses and cash outflows, (ii) its ability to obtain sufficient capital or strategic business arrangement to fund its operations, including the clinical trials for AMR-001, (iii) successful results of the Company's clinical trials of AMR-001 and other cellular therapeutic products that may be pursued, (iv) demand for and market acceptance of AMR-001 or other cell therapies if clinical trials are successful and the Company is permitted to market such products, (v) establishment of a large global market for cellular-based products, (vi) the impact of competitive products and pricing, (vii) the impact of future scientific and medical developments, (viii) the Company's ability to obtain appropriate governmental licenses and approvals and, in general, future actions of regulatory bodies, including the FDA and foreign counterparts, (ix) reimbursement and rebate policies of government agencies and private payers, (x) the Company's ability to protect its intellectual property, (xi) the company's ability to successfully divest its interest in Erye, and (xii) matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

Read the original post:
NeoStem to Present at Noble Capital Markets' Life Sciences Exposition on September 24

Posted in Cell Therapy | Comments Off on NeoStem to Present at Noble Capital Markets’ Life Sciences Exposition on September 24

Louise Phanstiel Joins Verastem Board of Directors

Posted: September 19, 2012 at 5:13 pm

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Verastem, Inc., (VSTM) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced the appointment of S. Louise Phanstiel to its Board of Directors. Louise Phanstiel was most recently the President of Specialty Products at WellPoint, Inc. and currently serves on the Board of Directors of Myriad Genetics and Cedar Sinai Health System.

Louise is a healthcare leader with strategic and financial experience at the highest level, said Christoph Westphal, M.D., Ph.D., Chairman and CEO of Verastem. On behalf of Lead Director Henri Termeer and the Verastem Board of Directors, I welcome her and look forward to her contributions as we continue the development of our portfolio of cancer stem cell-targeted candidates with the initiation of Phase 2 trials planned for 2013.

Verastem is leveraging its scientific expertise to eliminate cancer stem cells based on the groundbreaking work of Dr. Robert Weinberg, said Louise Phanstiel. This approach may be the key to providing a durable clinical response for serious cancers, one of the most pressing issues in all of healthcare. I am delighted to become a part of the team and work on this transformative approach to cancer treatment.

S. Louise Phanstiel has held several executive positions at WellPoint, Inc., including: President, Specialty Products; Senior Vice President, Chief of Staff and Corporate Planning; and Senior Vice President, Chief Accounting Officer and Controller and CFO of all of WellPoint subsidiaries, including Blue Cross of California. Prior to WellPoint, Ms. Phanstiel was a Partner, Los Angeles Cluster Insurance Leader at Coopers & Lybrand, LLP. She currently serves on the board of Myriad Genetics and Cedar Sinai Health System. Ms. Phanstiel received her BA in accounting from Golden Gate University in San Francisco, CA.

AboutVerastem, Inc.

Verastem, Inc.(VSTM) is a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. For more information please visitwww.verastem.com.

Forward-looking statements:

This press release includes forward-looking statements about the Companys strategy, future plans and prospects, including statements regarding the development of the Companys compounds and the expected timing of certain phase 2 clinical trials. The words anticipate, believe, estimate, expect, intend, may, plan, predict, project, target, potential, will, would, could, should, continue, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include the risks that the preclinical testing of the Companys compounds may not be predictive of the success of later clinical trials, that the Company will be unable to successfully complete the clinical development of its compounds, that the development of the Companys compounds will take longer or cost more than planned, and that the Companys compounds will not receive regulatory approval or become commercially successful products. Other risks and uncertainties include those identified under the heading Risk Factors in the Companys Annual Report on Form 10-K for the year ended December 31, 2011 and in any subsequent SEC filings. The forward-looking statements contained in this presentation reflect the Companys current views with respect to future events, and the Company does not undertake and specifically disclaims any obligation to update any forward-looking statements.

Link:
Louise Phanstiel Joins Verastem Board of Directors

Posted in Stem Cell Videos | Comments Off on Louise Phanstiel Joins Verastem Board of Directors

GeneCell International an International Leader in Cord Blood and Dental Pulp Stem Cells Expands to India

Posted: September 19, 2012 at 5:13 pm

Miami, FL (PRWEB) September 19, 2012

GeneCell International, an international leader in the processing and preservation of umbilical cord blood stem cells, announced today the expansion of its services into the country of India.

The company, with its corporate headquarters located in Miami, Florida, privately collects, processes and stores stem cells from umbilical cord blood, cord tissue, dental pulp and adipose tissue that can later be used to treat a variety of diseases. GeneCell International has deep roots in Latin America and more than a decade of experience in helping parents make informed decisions that can lead to potentially life-saving possibilities. The company also plans to collaborate with the medical community to further educate the expecting parents on the benefits stem cells offer.

The expansion into India provides easy and accessible resources for parents looking to preserve viable adult stem cells from both umbilical cord blood and dental pulp, said GeneCells Director of Operations, Jose Cirino. GeneCell believes in offering the best support and advice to the medical community to ensure parents are given the best and most up to date information in making an informed decision on preserving their childs stem cells that can potentially save a life of a family member.

Cord blood is rich in stem cells and there is less risk for the recipients immune system to reject these cells, because certain immune cells found in the cord blood are not mature. These cells can later be used to treat a variety of diseases and blood disorders within the immediate family, are free of ethical debate and patients can get the treatment in about three weeks - as opposed to six to eight for bone marrow from an adult donor, added Dr. Todd R. Flower, Genecells Director of Research and Laboratory Operations.

Alongside its commitment to educating the public on the benefits of stem cell preservation, GeneCell is always on the forefront in providing information for those who may require stem cells for medical treatments. With more than a decade of experience, GeneCell has maintained a large presence in Latin America - promoting the practice and encouraging families to bank their childs stem cells to help protect their loved ones.

About Umbilical Cord Blood Preservation: Umbilical cord blood preservation is a process by which blood is collected from the umbilical cord of a newborn baby and is stored cryogenically in a specially-designated bank. According to the National Marrow Donor Program, cord blood contains cells that can be transfused to a patient to treat various diseases, including lymphoma and leukemia. The list of illnesses that can be treated with cord blood continues to grow. In addition, the cord blood can be used to treat the child from whom the blood was collected as well as some first-degree relatives who are a close genetic match, such as immediate family members. Cord blood banking is regulated by the U.S. Food & Drug Administration and each year more and more parents choose to save their childrens cord blood should the medical need arise.

About Dental Pulp Stem Cells: One of the major advantages one gets from harvesting stem cells from his own body is that there will be no rejection of these cells when they are harvested and subsequently re-implanted. In the future, medical researchers anticipate being able to use technologies derived from stem cell research to treat a wider variety of diseases including Parkinsons, Alzheimers, spinal cord injuries, diabetes, heart diseases, liver disease, multiple sclerosis, muscle damage and many other diseases. The discovery that human dental pulp tissue contains a population of multi-potent mesenchymal dental pulp stem cells with the ability to reproduce quickly for self-renewal and the ability to differentiate into functional odontoblast has revolutionized dental research and opened new avenues in particular for reparative and reconstructive dentistry and tissue engineering in general.

About GeneCell International: GeneCell International, LLC is a trusted provider of collection, processing and storage of umbilical cord blood, dental pulp (teeth), and adipose (fat) from which stem cells can be extracted to treat a variety of diseases and disorders. GeneCell operates state-of-the-art laboratories and storage facilities for the cord blood of thousands of clients, headquartered in Miami, Florida and with local offices in Central Florida, Colombia, Costa Rica, Dominican Republic, Honduras, India, Peru, Puerto Rico, and Venezuela.

For more information and to learn more about cord blood, dental pulp, adipose tissue stem cell banking benefits or other services visit http://www.genecell.com.

Original post:
GeneCell International an International Leader in Cord Blood and Dental Pulp Stem Cells Expands to India

Posted in Stem Cell Videos | Comments Off on GeneCell International an International Leader in Cord Blood and Dental Pulp Stem Cells Expands to India

BioTime CEO Michael D. West to Present at Stem Cells USA & Regenerative Medicine Congress 2012

Posted: September 19, 2012 at 5:13 pm

ALAMEDA, Calif.--(BUSINESS WIRE)--

BioTime, Inc. (NYSE MKT: BTX) announced that Chief Executive Officer Michael D. West, Ph.D. will present at the Stem Cells USA & Regenerative Medicine Congress 2012 in Cambridge, MA on Thursday, September 20, 2012. Dr. West will speak on Second Generation hES Cell-Based Therapies: Achieving Purity and Scalability in the Midst of Diversity in the session Developments in Novel Therapeutics. The presentation will be made available on BioTime's website at http://www.biotimeinc.com.

The Stem Cells USA & Regenerative Medicine Congress 2012, September 20-21, is North Americas leading commercial stem cell event. This years conference will focus on strategies and business models for navigating the stem cell and regenerative medicine marketplace for pharma, biotech, and investors.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is enhanced through subsidiaries focused on specific fields of application. BioTime develops and markets research products in the field of stem cells and regenerative medicine, including a wide array of proprietary ACTCellerate cell lines, HyStem hydrogels, culture media, and differentiation kits. BioTime is developing Renevia (formerly known as HyStem-Rx), a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. BioTime's therapeutic product development strategy is pursued through subsidiaries that focus on specific organ systems and related diseases for which there is a high unmet medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd. is developing therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte Corporation is developing therapeutic applications of stem cells to treat orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation, focuses on the diagnostic and therapeutic applications of stem cell technology in cancer, including the diagnostic product PanC-Dx currently being developed for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is developing applications of BioTime's proprietary induced pluripotent stem cell technology to reverse the developmental aging of human cells to treat cardiovascular and blood cell diseases. BioTime's subsidiary, LifeMap Sciences, Inc., markets GeneCards, the leading human gene database, and is developing an integrated database suite to complement GeneCards that will also include the LifeMap database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database. LifeMap will also market BioTime research products. BioTime's lead product, Hextend, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive licensing agreements. Additional information about BioTime can be found on the web at http://www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list:

http://phx.corporate-ir.net/phoenix.zhtml?c=83805&p=irol-alerts

Here is the original post:
BioTime CEO Michael D. West to Present at Stem Cells USA & Regenerative Medicine Congress 2012

Posted in Stem Cell Videos | Comments Off on BioTime CEO Michael D. West to Present at Stem Cells USA & Regenerative Medicine Congress 2012

Page 2,644«..1020..2,6432,6442,6452,646..2,6502,660..»